43 results about "Proteus vulgaris" patented technology

The invention discloses a longifolene derivative (2, 2, 8, 8-tetramethyl-4-atrane [5. 4. 0. 11, 9] dodecane-6-alkene obtained by rearrangement and reduction reaction and by taking isolongifolene ketoxime as a raw material. Besides, bacteria such as staphylococcus aureus, Klebsiella pneumonia, Escherichia coli, bacillus proteus vulgaris and pseudomonas aeruginosa can be inhibited by the longifolene derivative, and particularly, the longifolene derivative has a superior insecticidal effect on pests such as aphids and rice planthopper.

The invention relates to a gene chip for detecting important pathogenic bacteria in an aquatic product and a kit thereof. The gene chip comprises a solid phase carrier and an oligonucleotide probe; the oligonucleotide probe comprises one or more of the following nucleotide sequences: (1) DNA (Deoxyribonucleic Acid) sequences selected from proteus mirabilis 1, proteus vulgaris, salmonella, vibrio parahaemolyticus, vibrio cholerae, Listeria monocytogenes, staphylococcus aureus, streptococcus pyogenes, vibrio vulnificus, bacillus cereus cluster, Shigella and pathogenic Y. enterocolitica ail gene; (2) complementary DNA sequences of the DNA sequences selected in the (1); (3) complementary RNA (Ribonucleic Acid) sequences of the DNA sequences in the (1) or (2). The kit comprises the gene chip. The gene chip and the kit can be used for detecting the important pathogenic bacteria in an aquatic product, are convenient to operate, high in precision and strong in repeatability.

He invention discloses a drug-resistant klebsiella pneumoniae phage RDP-KP-20004 and application thereof, wherein the preservation number of the phage is CGMCC No.21407, and the whole gene is sequenced and then is found to have no virulence gene and lysogenic gene, and the drug-resistant klebsiella pneumoniae phage RDP-KP-20004 provided by the invention has higher temperature tolerance and wider acid-base tolerance range, has strong cracking effect on pathogenic Klebsiella pneumoniae BK-20004 in a poultry breeding environment, and provides a phage source for the industrial production of phage for the prevention and treatment of the pathogenic Klebsiella pneumoniae BK-20004 in the poultry breeding environment; the klebsiella pneumoniae phage BK-20004 provided by the invention has very good advantages in treating diseases infected with klebsiella pneumoniae, and is relatively high in titer and good in prevention and treatment effect; and good application prospects are realized in the prevention and control of poultry pathogenic proteus vulgaris.

The invention discloses a method for efficiently preparing micromolecular chondroitin sulfate and micromolecular hyaluronic acid by one step, and belongs to the technical field of bioengineering. According to the method, chondroitin sulfate ABC lyase derived from proteus vulgaris ATCC33420 is heterologously expressed, a signal peptide wapA is selected, and constitutive xylose promoter Pxyl and pHY300PLK vectors are used, and secreted expression of the chondroitin sulfate ABC lyase in bacillus subtilis is realized through induction by xylose; the micromolecular chondroitin sulfate and the micromolecular hyaluronic acid can be produced efficiently and continuously by a designed chondroitin lyase-enzyme membrane reactor. The method has the advantages that the food-grade bacillus subtilis serves as a host strain, and safety and reliability are realized; effective reference is provided for industrial green production of the micromolecular chondroitin sulfate and the micromolecular hyaluronic acid; energy conservation and emission reduction are realized, and economic and social benefits are remarkable.

The invention relates to the technical field of microorganisms, in particular to streptococcus symcsis 3-17 streptococcus and an application thereof. Experiment proves that the streptococcus providedby the invention is named as streptococcus symcsis sp.nov.3-17, and is registered and preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC 60684; and the streptococcus has broad spectrum resistance and long-term antagonizing stability, and can resist one or more of staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, proteus vulgaris, enterobacter cloacae and acinetobacter baumannii. The streptococcus GDMCC 6068 provided by the invention can be applied as probiotics, corresponding products capable of being practically applied can be prepared from the streptococcus GDMCC 6068, and the streptococcus GDMCC 6068 has quite application tremendous potential in the field of medicine and pharmacy.

An isolongifolenone oxime ether derivative is prepared by the following steps of: taking isolongifolenone as the raw material, synthesizing isolongifolenone oxime through addition-elimination reaction, and performing alkylation reaction of the isolongifolenone oxime. Simultaneously, the isolongifolenone oxime ether derivative disclosed by the invention can inhibit bacteria, such as staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, bacillus proteus vulgaris and pseudomonas aeruginosa, and fungus, such as Aspergillus niger, exserohilum turcicum, corn sheath blight, alternaria musae Bovr.et Bat. and colletotrichum musae; and the isolongifolenone oxime ether derivative has the excellent insecticidal action for insect pests, such as aphid and rice planthopper.

The invention discloses a kit for detecting clinically common pathogenic bacteria by adopting an RNA isothermal amplification melting curve method and applications of the kit, belonging to the technical field of biological detection. The kit can detect the 16S rRNA of the following 16 clinically common pathogenic bacteria: staphylococcus aureus, pseudomonas aeruginosa, klebsiella pneumoniae, escherichia coli, proteus mirabilis, enterobacter aerogenes, pseudomonas fluorescens, acinetobacter baumannii, salmonella typhimurium, enterobacter cloacae, enterococcus faecium, enterococcus faecalis, bacillus proteus vulgaris, staphylococcus epidermidis, onion klebsiella and stenotrophomonas maltophilia. The kit has the features of high specificity, high sensitivity, low pollution, and detection accuracy and rapidness, plays an important role in clinical rapid identification and detection analysis of microbes, and has the wide application prospect.

The invention discloses a chondroitin sulfate ABC lyase mutant with high thermal stability and application thereof, and belongs to the technical field of bioengineering. The chondroitin sulfate ABC lyase derived from proteus vulgaris is subjected to truncation mutation, site-specific mutagenesis is carried out on the basis of the truncation mutant, the mutant with obviously improved thermal stability is obtained, the half-life period of the obtained mutant at 37 DEG C is prolonged by 247 times compared with that of a wild type, the recombinant bacteria expressing the mutant ferment protein inbatches in a 3-L tank, and the protein expression quantity can reach 1.7 g / L. A new method is provided for industrial production of chondroitin sulfate and dermatan sulfate, and can also be used for eliminating mixed chondroitin sulfate in heparin preparation.

The invention relates to a compound amoxicillin breast injectant prescription and a preparation method thereof. The compound amoxicillin breast injectant prescription comprises a suspending aid, an antioxidant and a solid dispersion carrier which are prepared through a special process to obtain white to off-white oily suspension. The compound amoxicillin breast injectant prescription disclosed by the invention has the advantages of simple preparation process, stable content, easy injection and the like. The composition disclosed by the invention is compounded from amoxicillin, clavulanate potassium and prednisolone; compared with other amoxicillin patent preparations, the composition has drug-tolerant bacteria for penicillins, and also has a high inhibition effect on the chromosome exzymes generated by klebsiella peneumoniae, bacillus proteus vulgaris and bacteroides fragilis; prednisolone has anti-inflammatory and antiallergic functions, and has a synergistic effect on bacterial infection and allergic inflammation.

An effective therapeutic agent for keloids and / or hypertrophic scars is provided. Specifically, an elastic fiber regenerating agent consisting of chondroitinase ABC derived from Proteus vulgaris and a therapeutic agent for keloids and / or hypertrophic scars comprising the regenerating agent as an active ingredient are provided.

The invention provides an application of a dibenzimidazolamine compound to preparation of an antimicrobial medicine. The dibenzimidazolamine compound has a structure shown as formula (I), and is simple in structure. The dibenzimidazolamine compound is relatively good in in-vitro antimicrobial activity, and performs quite high inhibitory activity of gram positive bacteria, such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, bacillus subtilis, and micrococcus luteus, gram negative bacteria, such as escherichia coli, proteus vulgaris, pseudomonas aeruginosa, and salmonella typhi, and fungi, such as candida utilis, aspergillus flavus, saccharomyces cerevisiae, candida albicans, and candida. The dibenzimidazolamine compound is used for preparing an antibacterial and / or antifungal medicine.

The invention discloses a chondroitinase ABC producing recombinant yeast strain and application thereof and belongs to the technical field of bioengineering. According to the chondroitinase ABC producing recombinant yeast strain, chondroitinase ABC from Proteus vulgaris ATCC33420 is subjected to heterogeneous expression, and with pPIC9K carriers and through induction of methanol, secretory expression of the chondroitinase ABC in pichia pastoris GS115 can be achieve; by means of a designed chondroitinase ABC-enzymatic membrane reactor, efficient and continuous production of small-molecular chondroitin sulfate can be achieved, the chondroitinase ABC can be recycled and reutilized, and the production cost can be greatly reduced. By taking food-grade yeast as host strains, the chondroitinase ABC producing recombinant yeast strain can be safe and reliable, provide effective references for industrialized and green production of small-molecular chondroitin sulfate A, B and C, and meanwhile, save energy, reduce emission and achieve significant economic and social benefits.

The method is suitable for the technical field of bacteria detection, the invention discloses a triple TaqMan Real-Time PCR detection method for simultaneously distinguishing proteus mirabilis(P. mirabilis), proteus vulgaris (P.vulgaris) and proteus penesei (P.pennerei), and a kit. The primers and nucleotide sequences of proteusbacillus vulgaris are predicted through computer software, and three pairs (six) of primers capable of being used for simultaneously detecting three proteusbacillus vulgaris and nucleotide sequences of three probes are disclosed. The method has the characteristics of strong specificity, high sensitivity and accurate and reliable result. According to the method, the proteusbacillus vulgaris can be identified as a specific species while the proteusbacillus vulgaris isdetected, the defect that only proteus mirabilis can be distinguished in existing proteusbacillus vulgaris detection is overcome, the proteusbacillus vulgaris detection process is greatly simplified,the workload of operators is reduced, the detection period is shortened, and a powerful technical support can be provided for detecting the proteusbacillus vulgaris in the industries of medical treatment, medical detection and the like.

The invention provides application of Amomum tsao-ko oil to preparation of medicaments for treating bacterial infectious diseases. The bacteria is coagulase negative staphylococcus, Kurthia gibsonii, megacoccus, corynebacterium, enterococcus faecalis, bacillus, escherichia coli, Pseudomonas, Acinetobacter lwoffii, Chryseobacterium indologenes, Enterobacter cloacae, S.flexneri or proteus vulgaris. The medicine provided by the invention has antibacterial activity against gram positive bacteria and gram negative bacteria, as well as strong inhibitory effect on the resistant strains, and also has good antibacterial effect in vivo; in addition; and the medicament can effectively treat clinical infectious diseases caused by gram positive and gram negative bacteria of various types, and provides a novel clinical medicine choice.

The invention relates to fermentation production and preparation of an active product, belongs to the field of bioengineering and in particular relates to a prodigiosin (PG) producing strain as well as a preparation method and an application thereof. The PG producing strain is Proteus Vulgaris and is preserved on June 24th, 2013 in CGMCC (China General Microbiological Culture Collection Center) and has the preservation number of CGMCCNo.7815 and the preservation unit address of No.3 No.1 Courtyard, West Beichen Road, Chaoyang District, Beijing, Institute of Microbiology of Chinese Academy of Sciences. The PG producing strain can produce PG through fermentation, and an improved inorganic salt culture medium is adopted and is cultured for 18-24 hours at a culture temperature of 20-28 DEG C and a rotating speed of 150-300rpm, and yield of PG can be 80-120mg / L. The produced prodigiosin has an inhibitory activity to staphylococcus aureus, salmonella paratyphi, tritirachium album and pseudomonas aeruginosa and has a good application prospect in bio-preparation of the PG.

The invention discloses a chondroitin sulfate ABC lyase mutant and a secretory expression method thereof, and belongs to the technical field of bioengineering. According to the chondroitin sulfate ABClyase mutant and the secretory expression method thereof, site-directed mutagenesis is conducted on chondroitin sulfate ABC lyase from proteus vulgaris, secretory expression of the chondroitin sulfate ABC lyase is enhanced by fusing signal peptide, outer membrane protein knockout is conducted on a strain expressing the enzyme, and a culture strategy of the strain is further provided.

The invention discloses a single-chamber microbial electro-Fenton system and an application thereof. The single-chamber microbial electro-Fenton system comprises an anode, a cathode and an electrolytesolution; the anode and the cathode are arranged in a same single chamber; the anode comprises an anode base material formed by rolling multiple layers of carbon cloth and a plastic net, and the plastic net is arranged between the carbon cloth and used for separating the carbon cloth; mixed bacteria are loaded on the anode base material; the mixed bacteria are composed of rhodopseudomonas palustris, proteus vulgaris, bacillus toyonensis and alcanivorax pacificus; the cathode comprises a support made of a titanium mesh, and the support is filled with activated carbon powder loaded with graphene and cobalt; the electrolyte solution comprises sewage to be treated and added nutrient substances; and the mixed bacteria decompose organic matters in the sewage to be treated to generate electronsfor the cathode to use. The current density generated by degrading organic pollutants by the mixed bacteria loaded on the anode is high, the energy consumption required by the electro-Fenton reactionof the cathode can be met, and extra electric energy does not need to be consumed.

The invention provides a microbial antibacterial extract, which is derived from fruiting bodies of butyriboletus hainanensis and is an ethanol extract of the fruiting bodies of the butyriboletus hainanensis. The microbial antibacterial extract provided by the invention has a good antibacterial effect and has an inhibitory effect on staphylococcus aureus, staphylococcus epidermidis, bacillus subtilis, bacillus proteus vulgaris and the like, thus having a broad development space in the prevention and treatment of diseases caused by the staphylococcus aureus, the staphylococcus epidermidis, the bacillus subtilis, the bacillus proteus vulgaris and the like; therefore, the microbial antibacterial extract has a very good development and application prospect in the aspect of antibacterial drugs.

The invention relates to application of Lycojaponicumin B in preparation of an antibacterial drug and belongs to the field of medicine. The Lycojaponicumin B has good inhabiting effect on escherichia coli, pseudomonas fluorescens, staphylococcus aureus, proteus vulgaris and cryptococcus neoformans, so that the Lycojaponicumin B can serve as an antibacterial compound and is hopefully applied to the preparation of related drugs. The application of the Lycojaponicumin B in the preparation of the antibacterial drug is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high bacteriostasis activity of the Lycojaponicumin B is previously unimagined, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin B has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and treatment of bacterial infection obviously.

The invention discloses recombinant yeast for fermentation production of chondroitin sulfate with controllable molecular weight and an application of the recombinant yeast, and belongs to the technical field of bioengineering. Pichia pastoris GS115 is used as an original strain by utilizing a synthetic biological technology and a genetic engineering means, and chondroitin sulfate synthetic pathway related proteins including KfoC and KfoA from escherichia coli K4, chondroitin sulfate transferase C4ST or C6ST from mice, UDP-glucose dehydrogenase TuaD from bacillus subtilis and chondroitin sulfate lyase ABCI from proteus vulgaris are heterologously expressed in cells, so that production strains for synthesizing chondroitin sulfate A (CSA) and chondroitin sulfate C (CSC) are obtained, and chondroitin sulfate A and chondroitin sulfate C with specific molecular weights can be obtained by controlling the concentration of an inducer namely methanol and the induction time. According to the recombinant yeast, the chondroitin sulfate with controllable molecular weight and specific configuration is synthesized by utilizing a microbial fermentation carbon source for the first time.

The invention relates to fermentation production and preparation of an active product, belongs to the field of bioengineering and in particular relates to a prodigiosin (PG) producing strain as well as a preparation method and an application thereof. The PG producing strain is Proteus Vulgaris and is preserved on June 24th, 2013 in CGMCC (China General Microbiological Culture Collection Center) and has the preservation number of CGMCCNo.7815 and the preservation unit address of No.3 No.1 Courtyard, West Beichen Road, Chaoyang District, Beijing, Institute of Microbiology of Chinese Academy of Sciences. The PG producing strain can produce PG through fermentation, and an improved inorganic salt culture medium is adopted and is cultured for 18-24 hours at a culture temperature of 20-28 DEG C and a rotating speed of 150-300rpm, and yield of PG can be 80-120mg / L. The produced prodigiosin has an inhibitory activity to staphylococcus aureus, salmonella paratyphi, tritirachium album and pseudomonas aeruginosa and has a good application prospect in bio-preparation of the PG.

Disclosed is an effective therapeutic agent for keloid and / or hypertrophic scar. Specifically disclosed are: an elastic fiber-regenerating agent, which comprises chondroitinase ABC derived from Proteus vulgaris; and a therapeutic agent for keloid and / or hypertrophic scar, which comprises the regenerating agent as an active ingredient.

The invention discloses a strain of Proteus vulgaris derived from human intestinal flora, a new application of its fermented liquid and the components contained therein. The strain, named HA‑3151, is effective against common Gram-positive and Gram-negative pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli, enteritis Salmonella has obvious inhibitory effect. The bacterial strain, its fermented liquid and its components can be used in medicine, food manufacturing and research and development.

The invention discloses a Chinese-Western compound disinfectant used for laboratory disinfection and a preparation method thereof, belonging to the technical field of medicine; the ingredients of the disinfectant in the invention are composed of sassafras, amaranthus, purple back vegetable, yin xiangpi, oil Citrus leaves, garlic, salt bran, misty kudzu, sharp tail wind, sticky grass, wild chrysanthemum, willow root, scorpion tree lotus, chlorhexidine, povidone iodine and glutaraldehyde; the disinfectant of the present invention uses traditional Chinese and Western medicine The combined treatment method is more effective than the simple use of traditional Chinese medicine and western medicine. With the principle of sterilization, insecticide, disinfection and anti-inflammation, it can maximize the efficacy of Chinese medicine ingredients and western medicine, play a complementary and enhancing role, and improve the medicinal effect , has antimicrobial effect, can destroy the permeability barrier of cell wall, reduce the enzyme activity, denature the bacterial protein, and thus play a bactericidal effect. It is effective against Staphylococcus aureus, E. Bacteria, common Proteus, etc. have good sterilization and disinfection effects.

The invention discloses maca spray for external application. The maca spray comprises, by weight, 0.5-1.0% of maca extract liquid, 1.0-1.5% of cinnamon extracts, 0.1-0.15% of clove extract liquid, 0.1-0.15% of capsicum annuum extract liquid, 0.1-0.5% of cistanche deserticola extracts, 0.3-0.5% of chlorhexidine acetate, 0.05-0.075% of propolis and the balance water. The maca spray for external application has the advantages that antibacterial, inflammation diminishing, itching relieving and anti-fungal effects and the like can be realized, inhibition effects can be realized for hemolytic streptococcus, streptococcus pneumoniae, Escherichia coli bacteria, proteus vulgaris, salmonella paratyphi A, shigella dysenteriae, Escherichia coli, staphylococcus aureus, methicillin-resistant staphylococcus aureus, candida albicans, pseudomonas aeruginosa and the like, the maca spray can be used for inhibiting the Escherichia coli, the staphylococcus aureus, the candida albicans and the like and has little skin irritation, and good wetting effects can be realized.

The invention relates to a gene chip and a test kit for detecting important pathogenic bacteria in aquatic products, wherein the gene chip comprises a solid matrix and an oligonucleotide probe composed of one or more serials selected from the following serials: (1) DNA serials selected from the spacers of 16S-23rS DNA of salmonella, Vibrio parahaemolyticus, Vibrio cholerae, Listeria monocytogenes, staphylococcus aureus, Suppurative streptococcus, Proteus mirabilis, Proteus Vulgaris and Paneth Proteus, and ipaH Virulence gene of Shigella; (2) complement DNA serials of the DNA serials selected from (1); (3) complement RNA serials of the DNA serials selected from (1) or (2). The chip and the test kit comprise simple and convenient operation, high veracity and strong repeatability in detecting the important pathogenic bacteria in aquatic products.

The invention discloses antibacterial maca gel and a method for preparing the same. The antibacterial maca gel comprises 0.5-1.0% of maca extract liquid, 1.0-1.5% of cinnamon extracts, 0.1-0.15% of clove extract liquid, 0.1-0.15% of capsicum annuum extract liquid, 0.1-0.5% of cistanche deserticola extracts, 0.10-0.15% of benzalkonium bromide, 2.0-2.5%o of carbomer and the balance water. The antibacterial maca gel and the method have the advantages that antibacterial, inflammation diminishing, itching relieving and anti-fungal effects and the like can be realized by the antibacterial maca gel prepared by the aid of the method, inhibition effects can be realized for hemolytic streptococcus, streptococcus pneumoniae, Escherichia coli bacteria, proteus vulgaris, salmonella paratyphi A, shigella dysenteriae, Escherichia coli, staphylococcus aureus, methicillin-resistant staphylococcus aureus, candida albicans, pseudomonas aeruginosa and the like, the antibacterial maca gel is high in skin compatibility and can become effective fast, and good antibacterial effects can be realized.

The present disclose relates to a method for preventing the decomposition of urine. The method includes adding a chemical to a liquid urine solution in a collection device to alter the pH of the resulting solution to a level that substantially prevents or significantly reduces the metabolism and reproduction of bacteria such as Escherichia coli, Proteus vulgaris, and Pseudomonas. The chemical composition may be an acid, such as a particulate, non-toxic, food grade acid that lowers pH to less than about 5.5, but more specifically to less than 4.0. The chemical composition may be an alkaline compound, such as potassium hydroxide, that raises pH to more than about 11.5. This method may be implemented so that urine is treated in the collection container for a patient concurrently with the urine collection. A kit implementing the method is disclosed.